Cytek Biosciences, Inc. (CTKB)

Cytek Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	93.28	98.72	167.3	296.6	364.62	165.23
Short-Term Investments	168.45	179.15	95.11	44.55	-	-
Cash & Short-Term Investments	261.73	277.86	262.41	341.15	364.62	165.23
Cash Growth	-5.78%	5.89%	-23.08%	-6.44%	120.67%	448.54%
Accounts Receivable	56.63	60.59	55.93	48.86	29.76	16.99
Other Receivables	5.04	-	0.19	2.01	-0.13	1.11
Receivables	61.67	60.59	56.12	50.88	29.63	18.1
Inventory	51.91	44.01	61.17	48.78	32.57	23.05
Prepaid Expenses	2.85	4.64	3.99	4.45	4.21	0.91
Restricted Cash	-	0.03	0.33	2.9	-	0.89
Other Current Assets	10.32	9.32	8.04	5.88	0.71	0.45
Total Current Assets	388.49	396.45	392.06	454.02	431.73	208.62
Property, Plant & Equipment	29.2	28.13	29.26	27.57	5.85	2.14
Long-Term Investments	1.6	1.6	-	-	-	-
Goodwill	16.7	16.66	16.18	10.14	10.14	0.48
Other Intangible Assets	17.68	20.13	23.08	4.33	4.74	0.27
Long-Term Deferred Tax Assets	38.39	33.37	30.49	20.46	9.17	7.38
Other Long-Term Assets	2.86	3.16	3.39	2.96	1.67	1.09
Total Assets	494.92	499.5	494.46	519.48	463.31	219.98
Accounts Payable	7.63	5.53	3.03	4.81	3.03	2.94
Accrued Expenses	21.68	21.69	18.99	20.42	14.89	8.65
Short-Term Debt	0.6	4.16	-	-	-	2.77
Current Portion of Long-Term Debt	6.99	0.5	0.57	0.58	-	-
Current Portion of Leases	3.09	3.76	2.44	2.93	-	-
Current Income Taxes Payable	1.38	1.52	1.3	0.25	2.48	0.47
Current Unearned Revenue	29.78	26.61	24.13	14.54	8.1	4.29
Other Current Liabilities	4.06	3.9	5.76	5.52	4.68	7.42
Total Current Liabilities	75.21	67.66	56.23	49.04	33.18	26.54
Long-Term Debt	0.66	1.05	1.65	2.27	-	-
Long-Term Leases	13.49	7.55	9.48	12.31	-	-
Long-Term Unearned Revenue	16.32	16.1	15.13	13.12	9.79	3.46
Other Long-Term Liabilities	10.68	11.4	18.91	17.18	14.95	11.7
Total Liabilities	116.35	103.76	101.39	93.93	57.92	41.69
Common Stock	0.13	0.13	0.13	0.14	0.13	0.02
Additional Paid-In Capital	435.28	430.79	423.39	442.89	423.63	6.49
Retained Earnings	-57.66	-35.2	-29.18	-17.03	-19.61	-22.61
Comprehensive Income & Other	0.82	0.02	-1.28	-0.7	0.9	0.07
Total Common Equity	378.57	395.74	393.06	425.3	405.04	-16.03
Minority Interest	-	-	-	0.25	0.34	-
Shareholders' Equity	378.57	395.74	393.06	425.55	405.39	178.29
Total Liabilities & Equity	494.92	499.5	494.46	519.48	463.31	219.98
Total Debt	24.83	17.02	14.14	18.09	-	2.77
Net Cash (Debt)	236.91	260.85	248.27	323.06	364.62	162.46
Net Cash Growth	-10.01%	5.06%	-23.15%	-11.40%	124.44%	439.34%
Net Cash Per Share	1.85	2.00	1.84	2.33	4.47	4.98
Filing Date Shares Outstanding	127.86	128.1	130.82	135.43	134.08	31.24
Total Common Shares Outstanding	127.86	129.21	130.71	135.37	133.75	31.24
Working Capital	313.28	328.78	335.83	404.98	398.55	182.09
Book Value Per Share	2.96	3.06	3.01	3.14	3.03	-0.51
Tangible Book Value	344.2	358.95	353.8	410.82	390.16	-16.78
Tangible Book Value Per Share	2.69	2.78	2.71	3.03	2.92	-0.54
Buildings	7.78	7.76	7.65	5.55	-	-
Machinery	17.43	15.33	12.79	7.63	4.35	1.97
Construction In Progress	0.85	0.36	0.26	0.18	0.34	-
Leasehold Improvements	3.61	3.22	3.62	3.48	3.02	1.11

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q